The US Food and Drug Administration (FDA) has granted tentative approvals to Zydus Cadila and Morepen Laboratories for treatments for schizophrenia and allergy symptoms, respectively.
In December 2021, Indian multinational Zydus Cadila received tentative approval from FDA to market its generic schizophrenia treatment, cariprazine.
Cariprazine is an atypical antipsychotic which targets dopamine receptors. It has been used in the treatment of schizophrenia and bipolar disorder and is sold under the brand name Vraylar by originator company AbbVie.
Zydus Cadila’s US subsidiary, Zydus Pharmaceuticals, received tentative approval for cariprazine capsules in 1.5 mg, 3 mg, 4.5 mg and 6 mg dosages for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder. The drug will be produced at Zydus Cadila’s manufacturing facility in Ahmedabad, India.
FDA approved Zydus Cadila’s neuroleptic drug, fluphenazine hydrochloride, in May 2021, which can also be used to treat schizophrenia [1]. The company also received US approvals for its ibrutinib and macitentan generics earlier in 2021 [2], used for the treatment of certain cancers and hypertension, respectively.
In related news, India’s Morepen Laboratories (Morepen) has also received tentative approval for its generic anti-allergy drug, fexofenadine hydrochloride. Fexofenadine is an antihistamine sold under the brand name Allegra by originator firm Sanofi Aventis. It is the most widely used second-generation antihistamine for the treatment of allergy symptoms and hay fever. Morepen sells the product in India under the brand name Fexopen.
Morepen confirmed in a statement that it has already supplied validation quantities and that regular commercial supplies would begin after approval of these validation batches.
Morepen’s Chairman and Managing Director, Sushil Suri, commented: ‘Approval of anti-allergy drug Fexofinadine by US FDA is an important milestone in the company's therapeutic journey since it consolidates Morepen's position in the anti-allergy market with already having US FDA approval for three lead products Loratadine, Desloratadine and Montelukast’.
Related articles
FDA reaches 100 generic approvals
COVID-19 vaccine progress and FDA approvals for Zydus Cadila
Zydus gets FDA approval for skin, heart and acid reflux generics
| LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Biosimilares aprobados en Colombia Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Biosimilares aprobados en Colombia iExplore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. FDA approval for schizophrenia and HIV generics from Zydus Cadila and Lupin [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from: www.gabionline.net/generics/news/fda-approval-for-schizophrenia-and-hiv-generics-from-zydus-cadila-and-lupin
2. GaBI Online - Generics and Biosimilars Initiative. Zydus Cadila and Sandoz generics approvals in North America [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from: www.gabionline.net/generics/news/Zydus-Cadila-and-Sandoz-generics-approvals-in-North-America
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
Source: Zydus Cadila; Morepen Laboratories
0
Post your comment